Pages that link to "Q38573379"

The following pages link to Animal models for studying dengue pathogenesis and therapy (Q38573379):

Displaying 31 items.

• Mouse models of dengue virus infection for vaccine testing (Q24276139) (← links)
• Dengue Fever: Causes, Complications, and Vaccine Strategies (Q26700082) (← links)
• A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates (Q27116692) (← links)
• Historical Perspectives on Flavivirus Research (Q29994534) (← links)
• 18F-FDG as an inflammation biomarker for imaging dengue virus infection and treatment response (Q30250993) (← links)
• Serum Metabolomics Investigation of Humanized Mouse Model of Dengue Virus Infection (Q33843566) (← links)
• Peripheral Organs of Dengue Fatal Cases Present Strong Pro-Inflammatory Response with Participation of IFN-Gamma-, TNF-Alpha- and RANTES-Producing Cells (Q36231756) (← links)
• A guinea pig model of Zika virus infection (Q37747543) (← links)
• Animal Models of Zika Virus (Q38158325) (← links)
• New developments in flavivirus drug discovery (Q38769771) (← links)
• Humanized mouse models to study human cell-mediated and humoral responses to dengue virus (Q40043632) (← links)
• A lethal model of disseminated dengue virus type 1 infection in AG129 mice (Q41930017) (← links)
• Peptides as Therapeutic Agents for Dengue Virus (Q45323856) (← links)
• A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model (Q47140392) (← links)
• Lucidone suppresses dengue viral replication through the induction of heme oxygenase-1. (Q47553003) (← links)
• Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants (Q47558465) (← links)
• Characterization of a murine model of non-lethal, symptomatic dengue virus infection. (Q52646073) (← links)
• Molecular Responses of Human Retinal Cells to Infection with Dengue Virus. (Q53126529) (← links)
• Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. (Q54110307) (← links)
• The use of humanized mice for studies of viral pathogenesis and immunity. (Q54244413) (← links)
• Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008 (Q56881264) (← links)
• Dengue Virus Infection of Primary Human Smooth Muscle Cells (Q58609208) (← links)
• An Industry Perspective on Dengue Drug Discovery and Development (Q59360236) (← links)
• The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication (Q61053654) (← links)
• Microneedle‐based intradermal delivery of stabilized dengue virus. (Q64892049) (← links)
• In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment (Q66679185) (← links)
• Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics (Q83225458) (← links)
• Dengue drug discovery: Progress, challenges and outlook (Q90825369) (← links)
• Pathogenesis and Immune Response Caused by Vector-Borne and Other Viral Infections in a Tupaia Model (Q92011762) (← links)
• A fluorescence-activatable reporter of flavivirus NS2B-NS3 protease activity enables live imaging of infection in single cells and viral plaques (Q92525535) (← links)
• A T164S mutation in the dengue virus NS1 protein is associated with greater disease severity in mice (Q93052134) (← links)